Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Azora Therapeutics (Nasdaq: AZR) reported a third-quarter 2026 net loss of $64.6 million while advancing AT177 toward initial clinical testing. Loss per share was $4.52, versus $2.02 a year earlier; the loss included a $57.1 million non-cash warrant-rights valuation charge. Cash fell to $22.0 million from $28.7 million at June 30.
Azora expects an investigational new drug application and Phase 1a trial initiation in the first half of 2027, subject to regulatory clearance. Manufacturing has begun, following completed toxicology studies. Optional milestone warrant purchases could provide up to approximately $32.4 million in gross proceeds. Preferred stock converted into 9,924,260 common shares on November 2, with further convertible shares outstanding. Formerly Adial Pharmaceuticals, the company adopted its new name and ticker October 29 and appointed new executives and directors.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Milestone warrant purchases could provide up to approximately $32.4 million in gross proceeds. 3.5× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Existing cash is anticipated to fund the current operating plan, including AT177 studies and Phase 1a, without milestone warrant proceeds.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Azora plans first-half 2027 application submission and Phase 1a single- and multiple-ascending-dose trial initiation.
- Moderate pointMilestone warrant rights liability of $80.9 million was reclassified to equity and no longer requires remeasurement.
- Minor pointAT177 toxicology studies completed; manufacturing to support clinical development has begun.
5 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Azora expects $38.5 million of preferred stock carrying value reclassified into stockholders’ equity in fourth-quarter 2026.
- Minor pointSeptember 30 cash of $22.044 million exceeded $5.881 million at December 31, 2025, despite the sequential decline.
- Minor pointWorking capital rose to $17.321 million at September 30 from $4.784 million at December 31, 2025.
- Minor pointTotal assets rose to $22.528 million at September 30 from $6.674 million at December 31, 2025.
- Minor pointInterest income increased to $170,000 in third-quarter 2026 from $48,000; nine-month income rose to $275,000 from $107,000.
Negative
- Major pointThird-quarter net loss widened to $64.562 million, or $4.52 per share, from $1.794 million, or $2.02, in 2025.
- Major point. Forward-looking: it has not happened yet and may not happen.Milestone warrant funding depends on investor elections; purchases would add potentially dilutive securities.
- Moderate pointCash declined to $22.0 million at September 30, 2026, from $28.7 million at June 30.
- Moderate pointPreferred stock conversion issued 9,924,260 common shares on November 2, 2026, diluting existing holders.
- Moderate pointRemaining preferred stock is convertible into 3,006,341 common shares, subject to beneficial ownership limitations.
- Moderate pointStockholders’ deficit was $21.061 million at September 30, versus $5.277 million equity at December 31, 2025.
12 minor points
- Minor pointThird-quarter loss included a $57.108 million non-cash charge from changes in milestone warrant rights liability fair value.
- Minor pointThird-quarter research and development expense rose to $1.775 million from $521,000 in 2025.
- Minor pointThird-quarter general and administrative expense rose to $5.756 million from $1.243 million in 2025.
- Minor pointAT177 clinical trial initiation remains subject to regulatory clearance.
- Minor pointNine-month net loss widened to $118.574 million, or $17.41 per share, from $5.981 million, or $11.35, in 2025.
- Minor pointNine-month research and development expense increased to $2.648 million from $2.000 million in 2025.
- Minor pointNine-month general and administrative expense increased to $12.725 million from $3.914 million in 2025.
- Minor pointNine-month acquired in-process research and development expense was $46.185 million, versus none in 2025.
- Minor pointNine-month financing expense allocated to milestone warrant rights liability was $2.067 million, versus none in 2025.
- Minor pointNine-month loss on extinguishing Azora convertible promissory notes was $6.054 million, versus none in 2025.
- Minor pointEquity-method investment losses rose to $93,000 quarterly and $342,000 over nine months, from $77,000 and $339,000 in 2025.
- Minor pointStock-based compensation increased to $958,000 quarterly and $1.243 million over nine months, from $147,000 and $508,000 in 2025.
News Explained
The warrant-rights liability no longer requires remeasurement; preferred stock’s carrying value is still expected to move into equity in the fourth quarter.
In its third-quarter report, Azora says cash of
After September amendments, the
Following stockholder approval on
Key Figures
- Cash and cash equivalents
- $22.0 million
- As of September 30, 2026; compared with $28.7 million as of June 30, 2026
- Net loss
- $64.6 million
- Three months ended September 30, 2026
- Loss per share
- $4.52 per basic and diluted share
- Three months ended September 30, 2026
- Non-cash fair-value charge
- $57.1 million
- Milestone warrant rights liability; included in third-quarter net loss
- Potential milestone warrant proceeds
- Up to approximately $32.4 million in gross proceeds
- Could be received if investors elect to purchase the milestone warrants
- Planned IND submission and Phase 1a trial initiation
- First half of 2027
- Planned; trial initiation is subject to regulatory clearance
Key Terms
ahr agonist medical
glp toxicology technical
gmp manufacturing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Azora Therapeutics commenced trading on Nasdaq as “AZR”
New executive team and Board of Directors appointed
AT177 IND submission and Phase 1a initiation on track for the first half of 2027
LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR) (“Azora” or the “Company”), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026.
During the quarter, Azora continued to advance AT177 through IND-enabling studies and expanded its scientific and operating team. AT177 is a proprietary, oral, colon-targeted aryl-hydrocarbon receptor (AhR) agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure.
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis,” said Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer. “We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”
Corporate Highlights
- New name and Nasdaq ticker. Effective October 29, 2026, the Company changed its name from Adial Pharmaceuticals, Inc. to Azora Therapeutics, Inc., and its common stock began trading on The Nasdaq Capital Market under the symbol “AZR.”
- Stockholder approvals. On October 28, 2026, the Company’s stockholders approved all remaining transaction matters, including the conversion of the Series A preferred stock and the exercise of the pre-funded and milestone warrants. On November 2, 2026, 9,924.260 shares of Series A preferred stock converted into 9,924,260 shares of common stock. The remaining 3,006.341 shares of Series A preferred stock remain outstanding and convertible into 3,006,341 shares of common stock, subject to beneficial ownership limitations.
New executive team
The following were appointed to executive roles at Azora effective October 28, 2026:
- Matt Davidson, Ph.D., Azora co-founder, was appointed President and Chief Executive Officer. He previously founded Verrica Pharmaceuticals and led development of the first FDA-approved treatment for molluscum contagiosum.
- Celia Economides was appointed Chief Financial Officer based on her more than 20 years of biopharma finance leadership across public and private companies.
- Julie Saiki, Ph.D., Azora co-founder, was appointed Chief Strategy Officer. Her research at Stanford helped establish AhR activation as a potential therapeutic approach for ulcerative colitis and provided the scientific foundation for AT177.
- David Rubenstein, M.D., Ph.D., joined as Chief Scientist. As Chief Scientific Officer of Dermavant Sciences, he led tapinarof (VTAMA® cream
1% ), the first FDA-approved AhR agonist, through development and approval.
New Board of Directors
On November 3, 2026, the Board appointed three independent directors, joining Dr. Davidson, who serves as Chair, and Wendy Young, Ph.D., former Senior Vice President of Small Molecule Drug Discovery at Genentech:
- Aida Habtezion, M.D., former Chief Medical Officer of Pfizer and former Stanford gastroenterologist whose research included the role of AhR in intestinal immunity.
- Paul Hastings, Chief Executive Officer of Nkarta and former Chair of the Biotechnology Innovation Organization (BIO).
- Thomas Soloway, Chief Executive Officer of T-knife Therapeutics and former Chief Financial Officer of Audentes Therapeutics and Ascendis Pharma, chairs the Audit Committee.
Milestone financing
On September 16 and September 30, 2026, the Company amended its securities purchase agreement and note exchange agreements to remove a provision that reduced investors’ milestone warrant purchase rights by the percentage of their initial closing pre-funded warrants exercised. Up to approximately
AT177 Program Update and Milestones
- IND-enabling studies continued, building on completed GLP toxicology studies and pre-IND feedback from the FDA.
- GMP manufacturing initiated to support clinical development of AT177.
- First half of 2027: Planned IND submission and initiation of a Phase 1a single- and multiple-ascending-dose (SAD/MAD) trial, subject to regulatory clearance.
Third Quarter 2026 Financial Results
Cash position
Cash and cash equivalents were
Research and development (R&D) expenses increased by approximately
General and administrative (G&A) expenses increased by approximately
Net loss was
Stockholders’ equity
As of September 30, 2026, the Company had a stockholders’ deficit of
About AT177
AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177 is a prodrug of the active ingredient, indirubin, a potent AhR agonist derived from indigo naturalis, a botanical extract that has been evaluated in clinical studies in patients with ulcerative colitis but has not been approved by the U.S. Food and Drug Administration. AT177's colon-targeted formulation is designed to deliver therapeutic AhR engagement directly to the colonic mucosa with the goal of minimizing the systemic AhR exposure associated with adverse effects. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure. AT177 is currently in IND-enabling studies, with an IND submission and Phase 1a clinical trial planned for the first half of 2027.
About Azora Therapeutics
Azora Therapeutics is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was launched out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns worldwide royalty-free rights to its technology, which is based on the development of oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. More information on Azora can be found on the company's website at www.AzoraTherapeutics.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include, but are not limited to, statements regarding advancing AT177 into the clinic in 2027; building long-term value for patients and shareholders; the aryl hydrocarbon receptor’s (“AhR”) potential to restore immune homeostasis and epithelial barrier function in UC; the targeted delivery strategy addressing an important limitation of earlier AhR agonists and positioning AT177 to capture the promise of localized AhR activation with a potentially better safety profile; remaining on track to submit an IND in the first half of 2027; existing cash and cash equivalents funding the Company’s current operating plan; the potential purchase of milestone warrants by investors; and the initiation of a Phase 1a SAD/MAD clinical trial planned to commence in the first half of 2027, followed by a Phase 1b proof-of-concept study in UC patients. Any forward-looking statements included herein reflect the Company’s current views, and they involve certain risks and uncertainties, including, among others, the Company’s ability to continue as a going concern and to raise additional capital when needed on acceptable terms or at all; the Company’s identified material weakness in internal control over financial reporting; the Company’s ability to submit an IND and initiate a Phase 1a SAD/MAD clinical trial in the first half of 2027, followed by a Phase 1b proof-of-concept study in UC patients; the Company’s ability to pursue its regulatory strategy; the ability to reproduce favorable results in clinical trials; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to develop strategic partnership opportunities and maintain collaborations; the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of its products; the Company’s ability to maintain its license agreements; the continued maintenance and growth of the Company’s patent estate and its ability to retain its key employees. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q (including Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Investor Contact:
Mike Moyer
Managing Director
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.com
Media Contact:
Ashley Biladeau
Inizio Evoke Comms
Ashley.Biladeau@inizioevoke.com
| AZORA THERAPEUTICS, INC. | ||||||||||||||||
| Condensed Statement of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development expenses(1) | $ | 1,775 | $ | 521 | $ | 2,648 | $ | 2,000 | ||||||||
| General and administrative expenses(1) | 5,756 | 1,243 | 12,725 | 3,914 | ||||||||||||
| Acquired in-process research and development | — | — | 46,185 | — | ||||||||||||
| Total Operating Expenses | 7,531 | 1,764 | 61,558 | 5,914 | ||||||||||||
| Loss From Operations | (7,531 | ) | (1,764 | ) | (61,558 | ) | (5,914 | ) | ||||||||
| Other Income (Expense) | ||||||||||||||||
| Interest income | 170 | 48 | 275 | 107 | ||||||||||||
| Change in fair value of milestone warrant rights liability | (57,108 | ) | — | (48,828 | ) | — | ||||||||||
| Financing expense allocated to milestone warrant rights liability | — | — | (2,067 | ) | — | |||||||||||
| Loss on extinguishment of Azora Therapeutics convertible promissory notes | — | — | (6,054 | ) | — | |||||||||||
| Loss on equity method investment | (93 | ) | (77 | ) | (342 | ) | (339 | ) | ||||||||
| Other income (expenses) | — | (1 | ) | — | 165 | |||||||||||
| Total other income (expense) | (57,031 | ) | (30 | ) | (57,016 | ) | (67 | ) | ||||||||
| Net Loss | $ | (64,562 | ) | $ | (1,794 | ) | $ | (118,574 | ) | $ | (5,981 | ) | ||||
| Loss per share, basic and diluted | $ | (4.52 | ) | $ | (2.02 | ) | $ | (17.41 | ) | $ | (11.35 | ) | ||||
| Weighted average shares, basic and diluted | 14,296,323 | 886,852 | 6,810,071 | 526,829 | ||||||||||||
(1) Includes stock-based compensation as follows (non-cash operating expenses):
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Research and development | $ | 213 | 4 | 220 | 10 | |||||||
| General and administrative | 745 | 143 | 1,023 | 498 | ||||||||
| Total stock-based compensation expense | $ | 958 | $ | 147 | $ | 1,243 | $ | 508 | ||||
| AZORA THERAPEUTICS, INC. | ||||||||
| Condensed Balance Sheet Data | ||||||||
| (Unaudited) | ||||||||
| (in thousands) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Cash and cash equivalents | $ | 22,044 | $ | 5,881 | ||||
| Working capital | 17,321 | 4,784 | ||||||
| Total assets | 22,528 | 6,674 | ||||||
| Stockholders' (deficit) equity | $ | (21,061 | ) | $ | 5,277 | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Azora Therapeutics’ third-quarter 2026 financial results?
Azora reported a $64.6 million net loss, or $4.52 per share, compared with $1.8 million, or $2.02 per share, in third-quarter 2025. The loss included a $57.1 million non-cash charge for changes in the fair value of milestone warrant rights liability.
When does Azora Therapeutics plan to begin the AT177 Phase 1a trial?
Azora plans to submit an investigational new drug application and initiate its Phase 1a trial in the first half of 2027, subject to regulatory clearance. The trial is planned to test single and multiple ascending doses.
Does Azora Therapeutics expect its cash to cover the AT177 Phase 1a trial?
Azora anticipates existing cash and cash equivalents will fund its current operating plan, including completion of studies needed before clinical testing and the Phase 1a trial. That expectation does not assume proceeds from issuing and selling milestone warrants.